SpringWorks Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q4 2017 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: SpringWorks Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2017 to Q3 2024.
SpringWorks Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$57.9M, a 31% increase year-over-year.
SpringWorks Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$295M, a 8.59% increase year-over-year.
SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$343M, a 22.2% decline from 2022.
SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$281M, a 61.8% decline from 2021.
SpringWorks Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$173M, a 274% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$295M	-$57.9M	+$26.1M	+31%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-12
Q2 2024	-$321M	-$44.9M	+$37.9M	+45.8%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-07
Q1 2024	-$359M	-$93.9M	-$16.2M	-20.9%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-02
Q4 2023	-$343M	-$98.5M	-$20M	-25.5%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-27
Q3 2023	-$323M	-$84M	-$12.3M	-17.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-12
Q2 2023	-$311M	-$82.9M	-$13.8M	-20.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-07
Q1 2023	-$297M	-$77.7M	-$16.2M	-26.4%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-02
Q4 2022	-$281M	-$78.5M	-$22.7M	-40.6%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-27
Q3 2022	-$258M	-$71.7M	-$30.8M	-75.4%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-02
Q2 2022	-$227M	-$69M	-$22M	-46.8%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-02
Q1 2022	-$205M	-$61.5M	-$31.7M	-107%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-03
Q4 2021	-$173M	-$55.8M	-$67M	-597%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-27
Q3 2021	-$106M	-$40.9M	-$19.3M	-89.4%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$87.2M	-$47M	-$27.2M	-137%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	-$60M	-$29.8M	-$13.6M	-84.5%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	-$46.3M	$11.2M	+$28.6M		Oct 1, 2020	Dec 31, 2020	10-K	2023-02-28
Q3 2020	-$74.9M	-$21.6M	-$6.26M	-40.9%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	-$68.7M	-$19.8M	-$4.97M	-33.5%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-04
Q1 2020	-$63.7M	-$16.1M	-$4.44M	-38%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-05
Q4 2019	-$59.2M	-$17.4M	-$10.9M	-169%	Oct 1, 2019	Dec 31, 2019	10-K	2020-03-12
Q3 2019	-$48.3M	-$15.3M	-$10.1M	-193%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-12
Q2 2019	-$38.2M	-$14.9M	-$10.6M	-252%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-12
Q1 2019	-$27.6M	-$11.7M	-$9.1M	-351%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q4 2018	-$18.5M	-$6.45M	-$1.79M	-38.4%	Oct 1, 2018	Dec 31, 2018	10-K	2020-03-12
Q3 2018	-$16.7M	-$5.23M			Jul 1, 2018	Sep 30, 2018	10-K	2020-03-12
Q2 2018		-$4.22M			Apr 1, 2018	Jun 30, 2018	10-K	2020-03-12
Q1 2018		-$2.59M			Jan 1, 2018	Mar 31, 2018	10-K	2020-03-12
Q4 2017		-$4.66M			Aug 18, 2017	Dec 31, 2017	10-K	2020-03-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.